SCHEMBL21137980

SCHEMBL21137980

CCCC(=O)N[C@H]1C(O)O[C@H](COC(=O)[C@@H](N)C(C)C)[C@@H](O)[C@@H]1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGB P11216 1/20 0.40
▸ SLC5A1 P13866 1/20 0.37
▸ SLC5A2 P31639 1/20 0.37
▸ AMDHD2 Q9Y303 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ IARS1 P41252 2/20 0.34
▸ TLR4 O00206 1/20 0.34
▸ LARS1 Q9P2J5 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ HK1 P19367 2/20 0.32
▸ HK2 P52789 2/20 0.32
▸ CA1 P00915 2/20 0.31
▸ CA2 P00918 2/20 0.31
▸ CA9 Q16790 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28855878 1.00 PYGB (0.40) PYGBSLC5A1SLC5A2AMDHD2ALDH1A1
Hydrochloric Acid SCHEMBL21058387 0.99 PYGB (0.39) PYGBSLC5A1SLC5A2AMDHD2ALDH1A1
Hydrochloric Acid SCHEMBL29777443 0.99 PYGB (0.39) PYGBSLC5A1SLC5A2AMDHD2ALDH1A1
Hydrochloric Acid SCHEMBL31353002 0.91 PYGB (0.41) PYGBAMDHD2ALDH1A1THRBKDM4E
Hydrochloric Acid SCHEMBL31352996 0.90 IARS1 (0.42) PYGBAMDHD2ALDH1A1THRBKDM4E
SCHEMBL21137861 0.87 MAPT (0.34) PYGBSLC5A1SLC5A2MAPK1TLR4
SCHEMBL21137926 0.87 PYGB (0.33) PYGBSLC5A1SLC5A2MAPK1TLR4
Hydrochloric Acid SCHEMBL31353001 0.85 PYGB (0.38) PYGBAMDHD2ALDH1A1THRBKDM4E
SCHEMBL21138667 0.84 PYGB (0.36) PYGBAMDHD2ALDH1A1THRBKDM4E
Hydrochloric Acid SCHEMBL29777456 0.83 PYGB (0.36) PYGBAMDHD2KDM4ELMNACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115215911-B Glucosamine derivative, composition thereof and medical application thereof 润佳(苏州)医药科技有限公司 2024-07-05 — — CN disclosed
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-02-28 — — US disclosed
CN-115215911-A Glucosamine derivative, composition thereof and medical application thereof 润佳(苏州)医药科技有限公司 2022-10-21 — — CN disclosed
CN-109929001-B Glucosamine derivative, composition thereof and medical application thereof 润佳(苏州)医药科技有限公司 2022-07-08 — — CN disclosed
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-18 — — US disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, GLA PYGB 760/4885SLC5A1 15/4885SLC5A2 28/4885
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, GLA PYGB 760/4885SLC5A1 15/4885SLC5A2 28/4885
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885SLC5A1 10/4885SLC5A2 19/4885
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885SLC5A1 10/4885SLC5A2 19/4885
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof OGT, UGGT1, GLA PYGB 601/4885SLC5A1 10/4885SLC5A2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback